

Company Announcement

November 17, 2014

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

KVISTGAARD, Denmark, November 17, 2014 - Pursuant to Section § 28a of the Danish Act on Securities Trading, Bavarian Nordic A/S reports the following transactions of shares and related securities of Bavarian Nordic A/S by persons holding managerial responsibilities and/or persons/companies closely associated with such.

Claus Bræstrup Name

Member of the Board of Directors of Bavarian Nordic A/S Reason for transaction

Issuer Bavarian Nordic A/S DK0015998017 ID code/ISIN

Description **Shares** Transaction Sale

Trading date 13 November 2014 Market NASDAQ Copenhagen

Number 5,615

Market value (DKK) 1,047,427.50

Name Claus Bræstrup

Reason for transaction Member of the Board of Directors of Bavarian Nordic A/S

Bavarian Nordic A/S Issuer DK0015998017 ID code/ISIN

Description **Shares**

Transaction Subscription (exercise of warrants)

Trading date 14 November 2014 Market NASDAQ Copenhagen

5,000 Number Market value (DKK) 270,500.00

About Bavarian Nordic

Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com.

Contacts

Page 1 of 2 Company Announcement no. 28 / 2014

Bavarian Nordic A/S Hejreskovvej 10A Phone: +45 33 26 83 83 www.bavarian-nordic.com CVR-nr: 16 27 11 87 +45 33 26 83 80

Fax:

DK-3490 Kvistgård Denmark

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43 Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

CVR-nr: 16 27 11 87